Cancer Genomics Clinical Trials Fund: SCCT Program

Purpose and Program Overview

The Cancer Genomics Clinical Trials Fund is a specialised, one-off federal grant initiative administered by Cancer Australia. Operating under the broader Support for Cancer Clinical Trials (SCCT) Program, the fund provides dedicated capital to embed genomic research directly into industry-independent clinical trials. The strategic objective is to accelerate the translation of genomic discoveries into daily clinical practice, thereby advancing personalised medicine across the Australian healthcare system.

The program runs over three financial years to fund vital research infrastructure and trial activities. By providing targeted funding, the initiative serves as a structural mechanism to integrate precision oncology and genomic screening into public health trials. This directly supports the foundational objectives outlined in the National Framework for Genomics in Cancer Control and aligns with the strategic mandates of the Australian Cancer Plan.

For the medical research and clinical trial sectors, this grant drives structural innovation and long-term capability building. The program ensures that clinical trials remain entirely independent of industry influence, focusing strictly on patient-centric optimisation and medical breakthroughs. Additionally, it establishes a sustainable operational pipeline that enhances the capacity of multi-site collaborative groups to manage complex, data-driven genomic research.

Key Grant Details

• Grant Amount: Financial allocations are structured to support multi-site trial activities and the underlying clinical infrastructure. Specific financial ranges per entity are determined upon targeted selection.
• Application Dates: Timelines are managed natively by the program administrator over the specified multi-year operational period.
• Eligible Organisations: Strictly limited to Australia’s Multi-site Collaborative Cancer Clinical Trials Groups (CTGs).
• Co-contributions: No mandatory external co-contribution ratios are explicitly stated in the core framework.
• Location Applicability: National coverage across all Australian states and territories, with a strategic emphasis on expanding trial sites into regional, rural, and remote communities.

Priority Sectors

The program explicitly targets the Medical Research, Clinical Trials, and Healthcare Innovation sectors. Specifically, funding is prioritised for investigator-initiated, industry-independent genomic research groups targeting rare, less common, or highly segmented cancer subtypes.

Funding Scope

The funding is designed to provide targeted structural and operational support over a defined multi-year timeline:

• Funding Categories: Capital is allocated toward trial activity costs, genomic screening infrastructure, and cross-tumour protocol development.
• Technical Services Integration: Supported trials leverage designated National Technical Services, including the Cancer Research Economics Support Team and the Cancer Quality of Life Expert Service Team, to ensure socio-economic viability.
• Project Timeline: The targeted funding operates as a multi-year program running from financial year 2025–26 through to financial year 2027–28.

Eligibility Criteria

• Organisation Structure: Applicants must be recognised as one of Australia’s Multi-site Collaborative Cancer Clinical Trials Groups (CTGs).
• Research Design: Trials must be investigator-initiated and entirely industry-independent.
• Collaborative Framework: Applicants must demonstrate collaboration with specialised entities, such as the Genomics Cancer Clinical Trials Initiative (GCCTI), to manage cross-tumour trial protocols.
• Compliance and Governance: Organisations must satisfy all standard federal clinical trial compliance protocols, data privacy frameworks, and institutional health regulations.
• Registration Status: Eligible groups must maintain valid legal structures, proper business registrations, and regulatory compliance within Australia.

Eligible Activities and Expenses

• Trial Infrastructure: Establishing and maintaining genomic research platforms and multi-site clinical trial registries.
• Hiring and Staffing: Engaging clinical researchers, data analysts, and technical personnel required to run genomic protocols.
• R&D and Technical Upgrades: Integrating genomic screening, precision oncology tools, and advanced data-tracking technologies into existing trial workflows.
• Protocol Development: Designing and implementing cross-tumour genomic clinical trial protocols across multiple geographic locations.
• Regional Expansion: Funding operational costs associated with establishing and maintaining trial sites in regional, rural, and remote medical centres.

Assessment Process

This grant initiative is administered under a targeted structural framework. Evaluation and funding distribution are managed based on clear performance and strategic alignment criteria:

• Strategic Alignment: The extent to which the trial implements the objectives of the National Framework for Genomics in Cancer Control and the Australian Cancer Plan.
• Project Merit: The scientific validity, feasibility, and potential health outcomes of the proposed genomic trial protocols.
• Value for Money: Efficient allocation of funds toward independent, patient-centric research infrastructure and socio-economically viable clinical protocols.

Recent Program Updates

The rollout of the Cancer Genomics Clinical Trials Fund introduces a unified focus on precision oncology under the broader SCCT infrastructure. Notable framework updates include mandatory technical integration with national expert service teams to monitor trial quality of life metrics and economic viability. Additionally, recent guidelines emphasise geographic inclusion, mandating the expansion of clinical sites beyond metropolitan academic centres to reduce the national disease burden equitably.

Application Tips

• Ensure Industry Independence: Review trial protocols thoroughly to confirm that the research design remains completely independent of commercial or pharmaceutical industry influence.
• Engage Technical Networks: Establish early collaboration with the Genomics Cancer Clinical Trials Initiative (GCCTI) to refine cross-tumour genomic trial protocols.
• Address Geographic Gaps: Explicitly detail how the trial will incorporate regional, rural, and remote clinical sites to ensure equitable patient access.
• Align with National Frameworks: Document exactly how the proposed research activity supports the strategic goals of the National Framework for Genomics in Cancer Control.

Where to Get Help

Consider consulting a grant specialist like Pattens Group for a personalised eligibility assessment and expert assistance in preparing a strong, compliant and competitive application. Contact us today and get connected with Australia’s best grant specialist, boasting over 35 years of experience in the industry and a 100% success rate. For official guidelines, application details, templates, and further information, visit the official website of Cancer Genomics Clinical Trials Fund: SCCT Program and other associated Australian government websites.